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Leprosy is a chronic infectious disease that can lead 
to physical disability, social stigma and great suffering. 
As the disease is transmitted person to person, it has re-
mained endemic in some developing countries. From 
biblical times to the modern period, leprosy has been de-
scribed as a horrifying disease due to the physical appear-
ance of infected individuals. Leprosy results in disfigured 
limbs and creates marks of cultural dishonour that have 
caused “lepers” to remain on the darker side of society. 
Confirmed reports of leprosy first appeared approxi-
mately 600 BC in sacred Indian texts that describe an 
affected individual’s loss of finger and toe sensations. 
However, the disease originated in Eastern Africa or the 
Near East and spread with successive human migrations. 
Europeans and/or North Africans then introduced lep-
rosy into West Africa and the Americas within the past 
500 years (Monot 2005). 
Historically, leprosy was associated with social ex-
clusion and isolation in leper colonies was considered 
the only instrument of control until the mid XX century. 
The social exclusion of those affected by the disease was, 
at first, based on the religious belief that the patients 
were impure. In the second half of XIX century, which 
was also known as the bacteriologic era, the hypothesis 
that leprosy was caused by a transmissible agent con-
flicted with the alternative hypothesis of leprosy being a 
hereditary disease. Mycobacterium hansen was the first 
microorganism identified as a cause of disease in 1873, 
which provided a scientific basis for patients’ isolation. 
In the 1940’s, the introduction of treatment with dapsone 
brought hope for a cure and disease control, but for mul-
tibacillary (MB) leprosy patients, this progress meant 
lifelong treatment. Then, it was not until the 1970’s that 
multidrug therapy (MDT) with rifampicin provided an 
effective cure for MB cases after many years of treat-
ment. In 1981, which was 20 years after the international 
medical practice abandoned single-drug therapy for tu-
berculosis, the WHO recommended a standard leprosy 
treatment that consisted of two regimens: rifampicin and 
dapsone over six months for PB leprosy and rifampicin, 
clofazimine and dapsone over 24 months for MB leprosy 
or until skins smears became negative. 
In May 1991, the 44th World Health Assembly ad-
opted resolution WHA44.9, which committed the World 
Health Organization (WHO) to attaining global elimina-
tion of leprosy by the year 2000. The goal was to reduce 
the known prevalence of leprosy to below 1 in 10,000 
inhabitants. Furthermore, the implementation of MDT 
turned a previously lifelong disease into a curable one. 
Thus, given the resulting shorter disease duration, a 
rapid and significant reduction of the known prevalence 
was anticipated, along with a reduction of the burden of 
leprosy on health systems.
WHO’s Secretariat also predicted an important in-
cidence decrease to be reflected in case detection rate 
(CDR) (Nordeen 1991), despite the absence of any previ-
ous evidence of huge impact on transmission in conse-
quence of leprosy or tuberculosis isolation or treatment 
programs. The target of elimination of leprosy as a pub-
lic health problem through universal and efficient MDT 
assumed the reduction of health care period as well as 
the reduction in transmission.
In 1997, the WHO recommended reducing MB leprosy 
treatment from 24-12 months after the 7th Expert Com-
mittee Meeting stated in its final report that “based on the 
available information, it is possible that the duration of the 
current MDT regimen for multibacillary leprosy could be 
shortened to 12 months” (p. 37) (WHO 1998). This new 
reduction in disease duration enabled the global elimina-
tion target to be achieved by the end of the year 2000. 
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Significant improvements have occurred in the last 
two decades, as leprosy is no longer a lifelong disease 
and leprosy colonies for patient isolation are part of pub-
lic health history. However, leprosy remains a public 
health problem in many parts of the world due to its high 
incidence and transmission rate.
From 1990-1999, the CDR increased in all WHO re-
gions except for the Eastern Mediterranean and Western 
Pacific regions, where the CDR has remained less than 1.6 
per 100 thousand inhabitants since 1990 (WHO 2000).
In a scenario where a highly efficacious treatment and 
government commitment to provide access to drugs are 
present, once extensive treatment availability is reached, 
the hidden prevalence cases are mainly responsible for 
transmission and the known prevalence value variation in 
time will reflect the detection rate behaviour over time. 
Hence, reducing transmission presupposes timely case 
detection, to reduce the duration of the disease prior to 
diagnosis. As timely case detection may raise the known 
value of prevalence in the short term, the known preva-
lence value measures the disease burden on the health 
system, rather than the community, at a specific point in 
time and its variation reflects mainly operational, rather 
than epidemiological, trends. As a result, emphasis has 
shifted from using prevalence to CDR in recent years as 
the main epidemiological indicator for leprosy.
Data on leprosy are reported to the WHO from most 
countries except for those in the European Region. In 
this paper, we intend to review leprosy occurrence in the 
world based on data published by the WHO in the years 
2000, 2005 and 2010.
MATERIALS AND METHODS
We evaluated data published in the Weekly Epidemi-
ological Record (WER) in 2000, 2005 and 2010 (WHO 
2000, 2005, 2010). The WER presented rates of preva-
lence per 10,000 inhabitants and CDRs per 100,000 
inhabitants in 2000 and 2005, but only the numbers 
of prevalent cases and newly detected cases were pub-
lished in 2010. Rates for this year were estimated using 
population data from the United Nations Population Di-
vision (UN 2011).
We estimated the relative reductions in the preva-
lence rate and CDR in each five-year period. Negative 
numbers were used to represent a relative increase dur-
ing each period and the values are presented as percent-
ages. To depict data from the reporting countries, we 
used box-whisker plots. The Pearson correlation coeffi-
cient was used to evaluate collinearity of different indi-
cators, i.e., how they varied together.
We classified countries as highly endemic if they 
had reported a prevalence rate higher than 1 per 10,000 
inhabitants or a CDR higher than 9 per 100,000 inhabit-
ants in one of the years studied. 
RESULTS
The data sets included 148 countries or territories 
that had reported to the WHO in at least in one of the 
years studied; of these, 63 reported in 2000, 112 reported 
in 2005 and 141 reported in 2010. Published data repre-
sents the prevalence rate on January 1 of the publica-
tion year and the CDR for the previous year. Tables I-V 
present the prevalence rates and CDRs of leprosy in the 
selected years by region. 
Only four countries reported a higher prevalence rate 
in 2010 than in 2000, including Liberia, Sudan, Sri Lanka 
and Malawi and eight countries reported a higher CDR 
in 2009 than 1999, including Somalia, Congo, Zambia, 
Liberia, Bolivia, Malawi, Guinea-Bissau and Mexico. 
Fig. 1 shows the box-whisker plots of the relative per 
cent reduction in the prevalence rate and the CDR over 
each five-year period. Notably, the prevalence rate reduc-
tion was larger in the first five-year period, while the CDR 
reduction was larger in the second five-year period. 
Table VI presents the correlation coefficient of the 
prevalence data and CDR data. There were low correla-
tions between the 2000 prevalence and the 1999 CDR 
and between the 2010 prevalence and the 2009 CDR. 
These low correlations suggest important variations in 
mean disease duration, which likely result from the dis-
tribution of disease forms and from differential compli-
ance to the one-year treatment regimen recommended 
by the WHO for MB cases. 
In contrast, the correlation coefficient between the 
2005 prevalence and the 2004 CDR was very high at 
0.94, which suggested a very rigid prevalent case defini-
tion and uniform disease duration. However, this corre-
lation was not maintained in the correlation between the 
prevalence decrease and the CDR decrease in the follow-
ing five-year period, which can be seen in Table VII.
Fig. 2 shows prevalence data from the 36 countries 
and territories with at least one prevalence value higher 
than 1 per 10,000 inhabitants. According to WHO Re-
gion, 52.8% of these countries were in the Africa Region, 
11.1% were in the Americas, 22.2% were in the Western 
Pacific Region, 11.1% were in the Southeast Asia Region 
and 2.8% were in the Eastern Mediterranean Region. Fig. 
3 shows the CDR and prevalence data from countries 
with at least one CDR value greater than 9 per 100,000 
inhabitants. Of these 32 countries, 56.3% were located in 
the African Region, 6.3% were in the Americas, 18.8% 
were in the Western Pacific Region and 18.8% were in the 
Southeast Asia Region. Only 10 countries met only one of 
the high-endemicity criteria. Benin, Bangladesh and Sri 
Lanka reported CDR above 9 per 100,000 inhabitants, but 
the prevalence values for these countries were all below 1 
per 10,000 inhabitants. The highest reported prevalence 
values were 0.8 per 10,000 inhabitants in 2000 in Benin, 
0.9 per 10,000 inhabitants in 2000 in Bangladesh and 0.89 
per 10,000 inhabitants in 2010 in Sri Lanka.
Ethiopia, Paraguay, Sudan, American Samoa and 
Tonga reported high prevalence rates, but none of these 
CDRs was higher than 9 per 100,000 inhabitants. Tonga 
reported a high prevalence in 2005, but zero prevalence 
and no new cases in 2010, which represents a huge varia-
tion that can be partially explained by the small popula-
tion of the island. Late compliance to the WHO-recom-
mended MDT and subsequent discharge of patients is 
a hypothesis that should also be considered. Sudan and 
American Samoa reported prevalence rates higher than 
1 per 10,000 inhabitants in 2010. However, the hypoth-
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esis that the inclusion of data from South Sudan raised 
the prevalence by 0.8 in 2000 was not supported by the 
CDR reported in this period (8.3 per 100,000 inhabitants 
in 1999 and 4.5 per 100,000 inhabitants in 2009, a reduc-
tion of 46%). Paraguay reported high prevalence rates in 
2000 and 2005 and only demonstrated a small reduction 
in the CDR (5.8%) from 1999-2009. Ethiopia, which had 
a high prevalence in 2000, showed a 26% reduction in 
the CDR to reach a rate of 5.4 per 100,000 inhabitants in 
2010. Guinea-Bissau also had a high prevalence in 2000 
and showed an 86.5% increase in the CDR from 1999-
2009. Moreover, Guiana had a high prevalence in 2005, 
but demonstrated a 29.9% reduction in the CDR from 
2004-2009 (no data available for 2000).
TABLE I
Prevalence and detection of leprosy - Africa (WHO Region)
Prevalence rate per 10,000 inhabitants Case detection rate per 100,000 inhabitants
2000 2005 2010 1999 2004 2009
Algeria - 0.0 0.0 - 0 0.0
Angola 2.5 1.6 0.6 14.9 13.6 5.0
Benin 0.8 0.4 0.2 10.2 5.5 2.9
Burkina Faso 0.8 0.8 0.2 7.5 8.6 2.6
Burundi - 0.5 0.3 - 2.7 3.4
Cameroon 1.1 0.3 0.3 9.1 2.6 2.4
Central African Republic 1.5 1.1 0.7 11.8 10.1 5.7
Chad 1 0.6 0.5 14.5 4 4.4
Comoros - 1.1 2.4 - 18.9 44.3
Democratic Republic of the Congo 1 1.9 0.7 8.6 21.1 7.9
Congo 1.6 0.7 0.9 1.8 10.7 3.7
Côte d’Ivoire 1.3 0.5 0.4 10.9 6 4.5
Ethiopia 1.3 0.7 0.6 7.4 6.3 5.4
Gabon - - 0.2 - - 1.7
Gambia 1.1 0.7 0.2 9.4 4.7 2.0
Ghana 0.7 0.3 0.3 8.4 3.8 2.6
Guinea 2 1.0 0.5 32 11.19 6.5
Equatorial Guinea - - 0.5 - - 3.4
Guinea-Bissau 1.2 0.5 0.5 4.6 2.7 5.0
Kenya 0.2 0.1 0.1 0.8 0.4 0.4
Lesotho - 0.0 0.0 - 0.2 0.2
Liberia 1 - 3.1 6 - 10.8
Madagascar 4.7 2.5 0.8 51.6 20.5 7.8
Malawi 0.5 - 0.5 4.5 - 5.2
Mali 1.5 0.4 0.3 14.7 3 2.3
Mauritania - - 0.1 - - 1.0
Mozambique 3.9 2.4 0.5 28.7 22 5.2
Namibia - 0.0 0.0 - 0.4 0.2
Niger 2.3 0.5 0.3 18.2 5.6 3.7
Nigeria 0.6 0.4 0.3 6.3 4.1 2.7
Rwanda - - 0.0 - - 0.3
Senegal 0.5 0.4 0.3 5.1 3.7 2.2
Sierra Leone 3.1 0.9 0.6 8.5 11.2 8.0
United Republic of Tanzania 1.4 1.3 0.6 15.4 13.8 6.1
Togo 0.7 0.2 0.2 7.1 2.9 2.7
Uganda 0.5 0.3 0.1 4.1 2.4 1.1
Zambia 0.8 - 0.5 1.9 - 3.5
Zimbabwe - - 0.0 - - 0.0
Botswana - 0.1 - - 0.3 -
Cabo Verde - 0.3 - - 0.6 -
SaoTomé-et-Principe - 0.0 - - 0 -
Seychelles - 0.1 - - 0 -
South Africa - 0.0 - - 0.1 -
Swaziland - 0.0 - - 0.2 -
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DISCUSSION
In the year 2000, the WER only published data on 
leprosy from countries with more than 100 cases. The 
coverage of available country data became larger in 
2005 and 2010, which enabled an improved evaluation 
of leprosy occurrence in the world. 
Although data reported to WHO are not completely 
reliable, as published elsewhere (Murdur 2005, Penna 
& Penna 2007), and the drop of 29% from 2003-2004 
of India’s CDR (WHO 2005) suggests, the analysis of 
data published by WHO in the selected years may shed 
light on leprosy distribution in the world. Year 2000 was 
the year established by the WHO for attaining the global 
elimination target, 2005 the year established by WHO 
secretariat for attaining the more radical target of reach-
ing elimination at national and then sub-national levels, 
2010 is the year when more recent data were published. 
The greater prevalence reduction in the first five-year 
time period was expected, as prevalence reduction that 
is based on disease duration diminution through treat-
ment reaches an operational limit when MDT coverage 
reaches 100%. The backlog of known cases to be treated 
and cured by MDT, which was the main issue related 
to leprosy control programmes in the eighties and early 
nineties, has disappeared in the last decade, as treatment 
has been aimed mainly at newly detected cases. The high 
correlation between the 2005 prevalence rate and the 
2004 CDR indicates that mean disease duration is very 
homogeneous among the reporting countries and this 
TABLE II
Prevalence and detection of leprosy - Americas
Prevalence rate per 10,000 inhabitants Case detection rate per 100,000 inhabitants
2000 2005 2010 1999 2004 2009
Bolivia 0.1 0.1 - 0.9 1.1 1.4
Mexico 0.2 0.1 0.0 0.1 0.3 0.1
Paraguay 1.2 1.1 0.5 6.7 8.2 6.3
Ecuador 0.2 0.1 0.1 0.6 1.1 0.6
Cuba 0.5 0.2 0.2 3 1.9 2.3
Brazil 4.3 1.7 1.9 25.9 26.9 19.2
Argentina 0.5 0.2 0.2 1.3 1 0.8
Dominican Republic 0.4 0.4 0.3 2.7 2.2 1.7
Venezuela 0.6 0.5 0.6 3.3 2.6 2.0
Colombia 0.8 0.3 0.2 1.7 1.2 1.0
Suriname 2.3 0.7 0.5 14.6 10.8 7.2
Costa Rica 0.4 0.0 0.1 0.4 0.2 0.2
Peru 0.1 - 0.0 0.3 - 0.1
Netherlands Antilles - - 0.0 - - 0.0
Antigua and Barbuda - - 0.0 - - 0.0
Bahamas - - 0.0 - - 0.0
Barbados - - 0.0 - - 0.0
Belize - - 0.0 - - 0.0
British Virgin Islands - - 0.0 - - 0.0
Chile - 0.0 0.0 - 0 0.0
Dominica - - 0.1 - - 1.4
El Salvador - 0.1 0.0 - 0.1 0.1
Grenada - - 0.2 - - 0.0
Guatemala - 0.0 0.0 - 0 0.0
Guyana - 1.3 0.8 - 4.9 3.8
Honduras - 0.0 0.0 - 0 0.0
Jamaica - 0.1 0.0 - 0.3 0.3
Montserrat - - 0.0 - 0.0
Nicaragua - - 0.0 - - 0.1
Panama - 0.0 0.0 - 0.1 0.0
Saint Kitts - - 0.0 - - 0.0
Saint Lucia - 0.9 0.3 - 8.2 4.6
Saint Vincent and the Grenadines - - 0.0 - - 0.0
Trinidad and Tobago - 0.4 0.3 - 1.8 1.9
Uruguay - - 0.0 - - 0.2
United States of America - 0.0 0.0 - 0 0.0
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finding is likely a result of very high compliance to the 
WHO-recommended MDT. However, the lack of a cor-
relation between the decrease in the prevalence rate and 
the CDR between 2005 and 2010 does not support this 
hypothesis and an alternative hypothesis is that this cor-
relation was a consequence of changes to the prevalent 
case definition, i.e., the discharge of newly diagnosed 
cases turned prevalence into a linear function of CDR.
The criteria we used to classify a country as high-
ly endemic consisted of the prevalence cut-point used 
by the WHO to declare leprosy eliminated as a public 
health problem and a similar criterion for CDR has been 
reported. Our criterion was established in accordance 
with a health surveillance perspective that used data to 
monitor recent M. hansen circulation in the community. 
The highly endemic countries in our study were located 
TABLE IV
Prevalence and detection of leprosy - Southeast Asia (WHO Region)
Prevalence rate per 10,000 inhabitants Case detection rate per 100,000 inhabitants
2000 2005 2010 1999 2004 2009
Afghanistan 0.1 0.0 - 0.1 0.1 -
Bangladesh 0.9 0.5 0.28 11.4 5.9 3.54
Bhutan - 0.2 0.41 - 0.8 1.67
East Timor - 5.0 1.49 - 41.9 14.51
India 5 1.4 0.71 54.3 23.9 11.00
Indonesia - 0.9 0.87 - 7.5 7.22
Maldives - 0.2 0.22 - 2.5 3.51
Myanmar 5.9 0.5 0.58 62.9 7.5 6.56
Nepal 5.7 1.8 0.81 78.7 26.2 14.86
Sri Lanka 0.7 0.7 0.87 9.4 9.7 8.94
Thailand 0.4 0.2 0.11 1.4 1 0.43
TABLE III
Prevalence and detection of leprosy - Eastern Mediterranean (WHO Region)
Prevalence rate per 10,000 inhabitants Case detection rate per 100,000 inhabitants
2000 2005 2010 1999 2004 2009
Bahrain - - 0.00 - - 0.09
Djibouti - 0.0 0.11 - 0 0.23
Egypt 0.5 0.3 0.11 2.2 1.7 0.87
Iran 0.0 0.0 0.01 0.1 0.1 0.04
Iraq - - 0.00 - - 0.00
Jordan - - 0.00 - - 0.00
Kuwait - 0.0 0.00 - 0 0.04
Lebanon - 0.0 0.01 - 0.1 0.07
Libyan Arab Jamahiriya - 0.0 0.01 - 0.1 0.08
Morocco - 0.1 0.02 - 0.2 0.13
Occupied Palestinian Territory - 0.0 0.00 - 0 0.00
Oman - 0.0 0.01 - 0.1 0.07
Pakistan 0.1 0.1 0.05 0.6 0.4 0.31
Qatar - - 0.19 - - 2.88
Saudi Arabia - 0.0 0.01 - 0.1 0.00
Somalia 0.3 0.4 0.05 0.4 2.3 1.19
Sudan 0.8 - 1.37 8.3 - 4.92
Syrian Arab Republic - 0.0 0.00 - 0 0.02
Tunisia - - 0.00 - - 0.01
United Arab Emirates 0 - 0.00 0 - 0.00
Yemen 0.3 0.2 0.18 3.2 2 1.65
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in the tropical areas of South America, Africa, the In-
dian subcontinent and Pacific and Indian Ocean Islands 
and many of these countries consist of small islands or 
regions with a very humid climate (Fig. 4). 
The leprosy problem in many Pacific islands is well 
researched. Worth (1996) documented the end of the lep-
rosy epidemic in Hawaii, where the CDR decreased 80% 
from 1900-1950 among Hawaiians and part-Hawaiians, 
which represents a mean annual reduction of 3.5% per 
year. This paper also noted the introduction of leprosy 
into Nauru and Micronesia in the 1920’s. In 1999, Ha-
waii had a CDR of 1.8 cases per 100,000 inhabitants, 
although imported cases from the Marshall Islands and 
Micronesia, where leprosy still produces many cases, 
are still diagnosed in Hawaii (Ong et al. 1999) and other 
United States of America (USA) states (Woodall et al. 
2011). No secondary cases reaching natives have been 
linked to these imported cases in Hawaii or USA and 
this break in transmission points to the importance of 
socioeconomic factors in leprosy transmission.
This epidemiological pattern raises the question of 
how leprosy persistence occurs in these islands, as most 
infectious agents that are transmitted by direct contact, 
i.e., from person to person, do not persist in very small 
and isolated populations. Leprosy persistence may be 
explained by the lifelong duration of leprosy disease in 
MB cases if the infection is not treated; however, if this 
mechanism were responsible for maintaining leprosy 
transmission in small populations, patient isolation would 
have a large impact on disease dynamics. Although some 
TABLE V
Prevalence and detection of leprosy - Western Pacific (WHO Region)
Prevalence rate per 10,000 inhabitants Case detection rate per 100,000 inhabitants
2000 2005 2010 1999 2004 2009
American Samoa - 0.6 1.19 - 4.8 4.48
Australia - 0.0 0.00 - 0 0.02
Brunei Darussalam - - 0.05 - - 0.51
Cambodia 0.5 0.3 0.20 7.2 3.3 2.50
China 0 0.0 0.02 0.2 0.1 0.12
China - Hong Kong SAR - 0.1 0.03 - 0.1 0.07
China - Macao SAR - 0.0 0.00 - 0.4 0.00
Cook Islands - 0.0 0.00 - 0 0.00
Fiji - 0.0 0.02 - 0.4 0.23
French Polynesia - - 0.37 - - 3.33
Guam - - 0.27 - - 3.34
Japan - 0.0 0.00 - 0 0.00
Kiribati - 3.0 5.56 - 66 95.29
Lao 0.5 0.4 0.15 3.2 3.7 1.63
Malaysia 0.5 0.3 0.24 1 1 0.67
Marshall Island - 9.2 11.95 - 103.3 80.88
Micronesia - 7.7 0.81 - 139.1 22.77
Mongolia - 0.0 0.00 - 0 0.00
Nauru - - 3.00 - - 30.00
New Caledonia - 0.0 0.16 - 0.1 2.79
Niue - 0.0 0.00 - 0 0.00
North Mariana Islands - - 0.14 - - 0.00
Palau - 3.0 1.95 - 30 19.51
Papua New Guinea 1.1 0.9 0.90 15.5 5.4 6.47
Philippines 0.6 0.4 0.29 4.5 2.8 1.95
Pitcairn Islands - 0.0 - - 0 -
Korea 0.1 0.1 0.06 0 0 0.01
Samoa - 0.4 0.22 - 5.4 2.72
Singapore - 0.0 0.02 - 0.1 0.16
Solomon Islands - 0.4 0.39 - 4.1 5.70
Tokelau - - 0.00 - - 0.00
Tonga - 2.0 0.00 - 1 0.00
Tuvalu - 0.0 0.67 - 0 0.00
Vanuatu - 0.5 0.21 - 1.4 2.13
Viet Nam 0.3 0.1 0.04 2.3 1 0.47
Wallis and Futuna - - - - - -
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impact on leprosy epidemiology has been attributed to 
isolation in Norway, the CDR decrease was slow (Irgens 
1980). The long latent period of infection may explain 
this epidemiological characteristic and it also may ex-
plain the slow CDR decrease caused mainly by the birth 
cohort effect, which states that individuals born in more 
recent years experience smaller risks of leprosy infection 
than older cohorts when transmission risk decreases. Ir-
gens (1980) has described the birth cohort effect in Nor-
way since the middle of the XIX century and Penna et al. 
(2012) described the same effect in the Brazilian state of 
Amazonas over the last 30 years. This birth cohort effect 
and the lack of an efficient way to detect and treat latency 
by chemoprophylaxis clearly reduces the probability of 
the complete disappearance of new leprosy cases in the 
medium term, as proposed by the WHO (2012).
Although the map in Fig. 4 poorly illustrates the lep-
rosy situation in Pacific Ocean and Indian Ocean island 
countries and territories, this map clearly shows a belt of 
highly endemic countries in tropical Africa. The Indian 
subcontinent is also a known area for high leprosy trans-
mission and, in the Americas, the Amazon Region has 
been acknowledged as a highly endemic region since the 
beginning of the XX century (Penna et al. 2009).
Although the distribution of leprosy by country is in-
teresting, we also know that leprosy is clustered in certain 
areas and subpopulations. However, improved knowledge 
of transmission mechanisms and human susceptibility is 
needed to support a control strategy that can have a sig-
nificant impact on Mycobacterium leprae transmission. 
Socioeconomic development has a known impact on the 
epidemiological behaviour of leprosy and local transmis-
sion of leprosy does not occur in developed countries. 
In the USA, new cases in American-born individu-
als attributed to local transmission occur in a delimited 
area of the Gulf Coast, mainly in the Mississippi delta. 
Moreover, recent work has shown that M. leprae can be 
found infecting both humans and wild nine-band arma-
TABLE VI
Correlations between reported indicators
Prevalence
Case detection rate
1999 2004 2009
2000 0.05 -0.00 -0.00
2005 0.20 0.94 0.67
2010 -0.00 -0.00 -0.03
TABLE VII
Correlations between relative declines of indicators
Prevalence decline
Case detection rate decline
1999-2004 2004-2009 1999-2009
2000-2005 0.34 - 0.01 0.34
2005-2010 - 0.03 0.09 0.06
2000-2010 0.04 0.03 0.38
Fig. 1: box-whiskers plot of the distribution of the percentage of reduction of prevalence and case detection rate reported by the World Health 
Organization region and five year period.
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dillos in this area (Truman et al. 2011) and leprosy trans-
mission by wild fauna, even though the agent was first 
introduced into the Americas by humans, makes leprosy 
eradication impossible because this disease may persist 
as a zoonosis. Wild armadillos naturally infected by lep-
rosy have also been found in different Brazilian regions 
(Deps et al. 2007). A case-control study in Texas found 
a significant association between leprosy and contact 
Fig. 2: prevalence data from countries with at least one prevalence report bigger than 1 per 10,000 habitants.
Fig. 3: case detection rate (CDR) reported by countries with at least one CDR report bigger than 9 per 100,000 habitants.
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with armadillos, but a stronger association was found 
between leprosy and a history of living in Mexico (Clark 
et al. 2008). Furthermore, cases in African chimpanzees 
raise the possibility that these animals could maintain 
leprosy transmission in Africa (Suzuki et al. 2010). 
Changes in leprosy magnitude in high-incidence 
areas will likely only be apparent after many years of 
work, but it is important to monitor this progress. Im-
provements in health information systems are also im-
portant to avoid the collection of unreliable data, as pre-
viously highlighted by Fine (2006, 2008). 
The Eighth WHO Expert Committee on Leprosy 
(WHO 2010) has recommended the use of a new indicator, 
the CDR of grade 2 disability cases (CDR-G2D) per one 
million inhabitants, arguing that it is more specific than 
the CDR. However, the CDR-G2D is less precise than the 
CDR due to small numbers in the numerator and this dif-
ference will make it difficult to use for monitoring small 
areas, i.e., small countries and local control programmes. 
Moreover, the CDR-G2D is influenced by early and late 
diagnoses and by the total incidence of leprosy, as mea-
sured by the total CDR. Interestingly, the health surveil-
lance tradition aims to implement more sensitive indica-
tors as a disease becomes rare, if the disease continues to 
be monitored. A new global goal of reaching a CDR-G2D 
of 1 per one million by 2020 has been suggested, which 
would mean obtaining a 9.12% reduction per year (Penna 
et al. 2011, Rodrigues & Lockwook 2011). 
Since the complete genome sequence of M. leprae 
was published by Cole et al. (2001), new perspectives for 
research have been created (Mira et al. 2004). However, 
old questions about leprosy still need to be addressed 
(Scollard 2005), including the transmission mechanisms 
of M. leprae, how its metabolism imposes intracellular 
reproduction and impedes culture growing, the human 
immune response to infection that determines disease 
presentation in different forms and the process of leprosy 
reaction episodes. Further research will advance knowl-
edge of this old disease, contribute to better targeted 
public health interventions and may make its eradication 
from human populations feasible. Meanwhile, leprosy 
control should be based on early diagnosis and treatment, 
along with socioeconomic development that has a known 
impact on the epidemiological of leprosy behaviour. 
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